^
    21d
    CHIRON: ATL001 in Patients with Advanced Unresectable or Metastatic NSCLC (clinicaltrials.gov)
    P1/2, N=27, Terminated, Achilles Therapeutics UK Limited | N=50 --> 27 | Trial completion date: Jul 2027 --> Sep 2024 | Recruiting --> Terminated | Trial primary completion date: Jul 2025 --> Sep 2024; Sponsor decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Keytruda (pembrolizumab) • ATL 001
    21d
    THETIS: ATL001 in Patients With Metastatic or Recurrent Melanoma (clinicaltrials.gov)
    P1/2, N=13, Terminated, Achilles Therapeutics UK Limited | N=40 --> 13 | Trial completion date: Jul 2027 --> Sep 2024 | Recruiting --> Terminated | Trial primary completion date: Jul 2025 --> Sep 2024; Sponsor decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • IL2 (Interleukin 2)
    |
    BRAF mutation • BRAF V600
    |
    Opdivo (nivolumab) • ATL 001
    11ms
    THETIS: ATL001 in Patients With Metastatic or Recurrent Melanoma (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Achilles Therapeutics UK Limited | Trial completion date: Dec 2027 --> Jul 2027
    Trial completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • IL2 (Interleukin 2)
    |
    BRAF mutation • BRAF V600
    |
    Opdivo (nivolumab) • ATL 001
    1year
    Long-Term Follow-Up Study of Patients Receiving ATL001 (clinicaltrials.gov)
    P2, N=1, Terminated, Achilles Therapeutics UK Limited | N=90 --> 1 | Trial completion date: Jul 2028 --> Oct 2023 | Not yet recruiting --> Terminated | Trial primary completion date: Jul 2028 --> Oct 2023; The long-term follow-up of patients is being migrated to the original (parent) study protocols (Trial ID: ATX-NS-001 / NCT: NCT04032847;Trial ID: ATX-ME-001 / NCT: NCT03997474). Consequently, the ATX-LTFU-001 study is being terminated by the Sponsor.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    ATL 001
    almost2years
    THETIS: ATL001 in Patients With Metastatic or Recurrent Melanoma (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Achilles Therapeutics UK Limited | Trial completion date: Dec 2023 --> Dec 2027 | Trial primary completion date: Jul 2023 --> Jul 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • IL2 (Interleukin 2)
    |
    BRAF mutation • BRAF V600
    |
    Opdivo (nivolumab) • ATL 001
    over2years
    A first-in-human clinical trial in adult patients with metastatic or recurrent melanoma of a personalised therapy targeting specific mutations that occur in all cancer cells within a single patient. Primer estudio en humanos en pacientes adultos con melanoma metastásico o recurrente, para la evaluación de una terapia personalizada que se dirige a mutaciones específicas que ocurren en todas las células de cáncer de un único paciente (clinicaltrialsregister.eu)
    P1/2, N=40, Ongoing, Achilles Therapeutics UK Limited
    New P1/2 trial
    |
    BRAF (B-raf proto-oncogene) • IL2 (Interleukin 2)
    |
    BRAF mutation • BRAF V600
    |
    Opdivo (nivolumab) • ATL 001